BridgeBio Pharma (BBIO) Expected to Announce Earnings on Thursday

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($1.09) per share and revenue of $4.04 million for the quarter.

BridgeBio Pharma Trading Up 10.6 %

BBIO traded up $3.34 during midday trading on Friday, hitting $34.90. The company had a trading volume of 3,372,917 shares, compared to its average volume of 3,171,595. BridgeBio Pharma has a twelve month low of $21.62 and a twelve month high of $41.04. The firm's 50-day simple moving average is $31.15 and its 200-day simple moving average is $27.59.

Insider Buying and Selling

In other BridgeBio Pharma news, CEO Neil Kumar sold 27,389 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $613,787.49. Following the transaction, the chief executive officer now owns 4,897,443 shares of the company's stock, valued at approximately $109,751,697.63. The trade was a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of BridgeBio Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the completion of the transaction, the insider now directly owns 22,055,375 shares in the company, valued at approximately $769,732,587.50. The trade was a 12.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,492,093 shares of company stock valued at $122,029,004 in the last 90 days. 24.66% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

BBIO has been the subject of several research reports. HC Wainwright restated a "buy" rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a research report on Thursday. Scotiabank raised their price objective on shares of BridgeBio Pharma from $48.00 to $49.00 and gave the company a "sector outperform" rating in a research report on Wednesday. Evercore ISI raised their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a research report on Monday, December 23rd. Finally, Bank of America raised their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, November 25th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $49.08.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.